Results 91 to 100 of about 2,212 (184)

The role of the NLRP3 inflammasome in gout

open access: yesJournal of Inflammation Research, 2011
Sarah R Kingsbury1,2, Philip G Conaghan1,2, Michael F McDermott1,21Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Molecular Medicine, University of Leeds,
Sarah R Kingsbury   +2 more
doaj  

Die medikamentöse Therapie der juvenilen idiopathischen Arthritis bei Kindern

open access: yes, 2009
ZusammenfassungDie Therapie der juvenilen idiopathischen Arthritis erfolgt durch eine Kombination von nichtsteroidalen Antirheumatika, systemischen und/oder intraartikulären Glukokortikoiden, klassischen Basistherapeutika, Immunsupressiva und Biologika ...
G. Horneff
core   +1 more source

A systems biology approach to identify key targets in KRAS/BRAF-mutated colorectal cancer

open access: yesDiscover Oncology
Background KRAS and BRAF mutations are critical oncogenic drivers in colorectal cancer (CRC), with distinct molecular and clinical implications. Methods To uncover genes differentially expressed between these mutations, we compared KRAS G12D- and BRAF ...
Shiva Shiravi   +6 more
doaj   +1 more source

Canakinumab i rilonacept per al tractament de les síndromes periòdiques associades a la criopirina

open access: yes
Síndromes periòdiques associades a criopirina; Canakinumab; Assaigs clínics; Rilonacept;Cryopyrin-Associates Periodic Syndrome; CAP; Clinical Trial; Síndromes periódicos asociados a criopirina; Ensayos ClínicosLes síndromes periòdiques associades a ...
Comitè d’Avaluació de Medicaments d’Ús Hospitalari (CAMUH)
core  

Correction to: Rilonacept (Interleukin‑1 Inhibition) for the Treatment of Pericarditis [PDF]

open access: yesCurrent Cardiology Reports, 2022
Wang, Tom Kai Ming, Klein, Allan L.
openaire   +1 more source

Rilonacept Reduces Pericarditis Recurrence Risk, Hospitalizations, and ED visits: Outcomes from the RESONANCE Patient Registry [PDF]

open access: yes
RILONACEPT REDUCES PERICARDITIS RECURRENCE RISK, HOSPITALIZATIONS, AND ED VISITS: OUTCOMES FROM THE RESONANCE PATIENT REGISTRYPaul C. Cremer, MD1, Michael S. Garshick, MD2,3, Sushil A.
Ryan, John J.   +13 more
core  

Targeting IL-1 in SLE-Associated Recurrent Pericarditis: A Case Series and Review of Mechanistic Rationale

open access: yes
Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus (SLE), yet optimal management remains poorly defined. Glucocorticoids are frequently used but are associated with toxicity and increased recurrence risk. Interleukin-1 (
Ilan Richter   +13 more
core   +1 more source

Recurrent Pericarditis in a Rugby Player: Imaging-Guided Therapy. [PDF]

open access: yesJACC Case Rep
Abuawad A   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy